Rituximab for primary chronic cold agglutinin disease: A prospective study of 37 courses of therapy in 27 patients

Blood

Volumn 103, Issue 8, 2004, Pages 2925-2928

  Berentsen, Sigbjørn ^a   Ulvestad, Elling ^b   Gjertsen, Bjørn Tore ^b   Hjorth Hansen, Henrik ^b   Langholm, Ruth ^b   Knutsen, Håvar ^b   Ghanima, Waleed ^b   Shammas, Fuad Victor ^b   Tjønnfjord, Geir E ^b  

^a HAUGESUND HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RITUXIMAB;

ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FEVER; FLOW CYTOMETRY; FLU LIKE SYNDROME; HISTOPATHOLOGY; HUMAN; INFECTION; MALE; MULTICENTER STUDY; MYALGIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY CHRONIC COLD AGGLUTININ DISEASE; PRIORITY JOURNAL; RELAPSE; REMISSION; RETREATMENT; SIDE EFFECT; TREATMENT OUTCOME;

EID: 1842474927     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-10-3597     Document Type: Article

References (32)

1. Berentsen S, Bo K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the "idiopathic" type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS. 1997;105:354-362.
2. Silberstein LE. B-cell origin of cold agglutinins. In: Atassi MZ, ed. Immunobiology of Proteins and Peptides. Vol VII. New York, NY: Plenum Press; 1994:193-205.
3. Ulvestad E, Berentsen S, Bo K, Shammas FV. Clinical immunology of chronic cold agglutinin disease. Eur J Haematol. 1999;63:259-266.
4. Berentsen S, Tjonnljord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol. 2001;115:79-83.
5. Michaux L, Dierlamm J, Wlodarska I, et al. Trisomy 3 is a consistent chromosome change in malignant lymphoproliferative disorders preceded by cold agglutinin disease. Br J Haematol. 1995;91:421-424.
6. Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am J Med. 1982;72:915-922.
7. Dacie J. Haemolytic anaemias associated with malignant lymphomas other than Hodgkin's disease and chronic lymphocytic leukaemia (CLL). In: Dacie J, ed. The Haemolytic Anaemias, Vol 4. London, United Kingdom: Churchill Livingstone; 1995:27-40.
8. Dacie J. Treatment and prognosis of cold-antibody AIHA. In: Dacie J, ed. The Haemolytic Anaemias. Vol 3. London, United Kingdom: Churchill Livingstone; 1992:502-508.
9. Hippe E, Jensen KB, Olesen H, Lind K, Thomsen PE. Chlorambucil treatment of patients with cold agglutinin syndrome. Blood. 1970;35:68-72.
10. Hillen HF, Bakker SJ. Failure of interferon-alpha-2b therapy in chronic cold agglutinin disease. Eur J Haematol. 1994;53:242-243.
11. Berentsen S, Tjonnfjord GE, Shammas FV, et al. No response to cladribine in five patients with chronic cold agglutinin disease. Eur J Haematol. 2000;65:88-90.
12. Engelhardt M, Jakob A, Ruter B, et al. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood. 2002;100:1922-1923.
13. Lee EJ, Kueck B. Rituxan in the treatment of cold agglutinin disease. Blood. 1998;92:3490-3491.
14. Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol. 2002;68:243-246.
15. Sparling TG, Andricevic M, Wass H. Remission of cold hemagglutinin disease induced by rituximab therapy [abstract]. CMAJ. 2001;164:1405.
16. Zaja F, Russo D, Fuga G, et al. Rituximab in a case of cold agglutinin disease. Br J Haematol. 2001;115:232-233.
17. Finazzi G. Rituximab in autoimmune cytopenias: for which patients? Haematologica. 2002;87:113-114.
18. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634-641.
19. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171:1581-1587.
20. Ulvestad E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol. 1998;60:93-100.
21. Ulvestad E, Berentsen S, Mollnes TE. Acute phase haemolysis in chronic cold agglutinin disease. Scand J Immunol. 2001;54:239-242.
22. Ulvestad E, Aarseth JH, Vedeler C, Nyland H, Myhr KM. The effects of interferon-α 2a on concentrations of immunoglobulins, complement and lymphocytes in patients with multiple sclerosis. Scand J Immunol. 2004;59:103-108.
23. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383-3389.
24. Sivaraman S, Venugopal P, Ranganathan R, et al. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lymphocytic leukemia. Cytokines Cell Mol Ther. 2000;6:81-87.
25. Kimby E, Geisler C, Hagberg H, et al. Rituximab (Mabthera) as single agent or in combination with interferon-α-2a as treatment of untreated and first relapse follicular and other low-grade lymphomas: a randomized phase II study M39035 [abstract]. Blood. 2000;96(suppl):577.
26. Camou F, Viallard JF, Pellegrin JL. Rituximab in cold agglutinin disease [in French]. Rev Med inteme. 2003;24:501-504.
27. Dacie J. Auto-immune haemolytic anaemia (AIHA): cold antibody syndromes I: idiopathic types: clinical presentation and haematological and serological findings. In: Dacie J, ed. The Haemolytic Anaemias. Vol 3. London, United Kingdom: Churchill Livingstone; 1992:210-239.
28. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues: WHO Classification of Tumours. Vol 3. Lyon, France: IARC Press; 2001.
29. Isaksson E, Bjorkholm M, Holm G, et al. Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. Br J Haematol. 1996;92:71-76.
30. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:3266-3274.
31. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
32. Hagenbeek A, Czuczman MS, Ghielmini M, et al. Rituximab therapy for indolent non-Hodgkin's lymphoma. Anticancer Drugs. 2002;13(suppl 2):S11-S17.